Does phentermine cause hair loss? It is a question raised by many individuals using this appetite suppressant for weight management. Phentermine is a sympathomimetic amine that suppresses appetite by stimulating noradrenaline release, but it does not hold a UK marketing authorisation and is not part of standard NHS treatment pathways. Whilst hair loss is not a recognised side effect in prescribing information, some users report increased shedding. The most likely explanation is telogen effluvium — a temporary condition triggered by rapid weight loss and nutritional deficiency rather than the drug itself. This article explores the evidence, contributing factors, and practical guidance.

Can Phentermine Cause Hair Loss?

Phentermine has no established direct pharmacological mechanism causing hair loss; shedding reported by users is most likely telogen effluvium driven by rapid weight loss and nutritional deficiency rather than the drug itself.

Not sure if this is normal? Chat with one of our pharmacists →

Phentermine is a sympathomimetic amine used as a short-term appetite suppressant to support weight loss in individuals with obesity. It works primarily by stimulating the release of noradrenaline in the hypothalamus, suppressing appetite. Whilst phentermine is not widely prescribed in the UK compared to countries such as the United States, it remains a topic of interest for those exploring pharmacological weight management options.

It is important to note that phentermine does not currently hold a UK marketing authorisation, and there is no MHRA-approved Summary of Product Characteristics (SmPC) for phentermine available on the Electronic Medicines Compendium (EMC). Hair loss is not listed as a recognised side effect in non-UK prescribing information for phentermine. A number of individuals taking phentermine have reported increased hair shedding; however, this association is based on anecdotal reports rather than confirmed pharmacovigilance data, and there is no established, direct pharmacological mechanism by which phentermine itself causes hair follicle damage or disruption.

The most likely explanation for hair loss experienced during phentermine use is telogen effluvium — a temporary, diffuse form of hair shedding triggered by physiological stress rather than the drug itself. This condition occurs when a significant proportion of hair follicles prematurely enter the resting (telogen) phase of the hair growth cycle, leading to noticeable shedding typically two to four months after a triggering event. Rapid weight loss and nutritional deficiencies — both of which can accompany phentermine use — are well-established triggers of telogen effluvium. Therefore, whilst phentermine may not directly cause hair loss, the circumstances surrounding its use may contribute to this outcome.

If you suspect phentermine or any other medicine is causing hair loss, you can report this to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

How Weight Loss Medicines May Affect Hair Growth

Weight loss medicines affect hair indirectly by promoting caloric restriction and nutritional deficiencies — particularly in iron, protein, and zinc — which shift hair follicles into the resting phase, causing diffuse shedding two to four months later.

The relationship between weight loss medications and hair health is largely indirect. When the body undergoes rapid or significant caloric restriction — as is common when appetite suppressants such as phentermine are used effectively — it may experience a form of physiological stress. This stress can disrupt the normal hair growth cycle, which consists of three phases: anagen (growth), catagen (transition), and telogen (resting/shedding).

Nutritional deficiencies are a key concern during periods of reduced food intake. The following nutrients are particularly associated with hair thinning and shedding when intake is inadequate:

• Iron and ferritin — low iron stores are one of the most common reversible causes of hair loss, particularly in women; testing is recommended before supplementing

• Protein — hair is composed primarily of keratin, a structural protein; inadequate dietary protein directly impairs hair growth

• Zinc — essential for hair follicle repair and growth

• Biotin (vitamin B7) — true biotin deficiency is uncommon in the UK; routine supplementation is not recommended unless deficiency is confirmed

• Vitamin D — some evidence suggests a link between low vitamin D levels and hair follicle cycling, though this evidence remains preliminary and testing should be clinically guided

When caloric intake is significantly reduced, the body prioritises essential physiological functions over non-vital processes such as hair growth. This metabolic reprioritisation can result in a shift of hair follicles into the telogen phase, leading to diffuse shedding typically two to four months after the triggering event. The effect is usually temporary, and hair regrowth generally resumes once nutritional status stabilises and weight loss slows to a more gradual pace.

Other weight loss medications, including GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have similarly been associated with telogen effluvium. Alopecia is listed as an uncommon adverse reaction in the UK SmPCs for both Wegovy and Saxenda, and both NICE TA875 (semaglutide) and NICE TA664 (liraglutide) acknowledge this in the context of their approved use. This reinforces the view that rapid weight loss — rather than any specific drug — is the primary driver of hair shedding in most cases.

Experiencing these side effects? Our pharmacists can help you navigate them →

Other Factors That Can Trigger Hair Shedding

Thyroid dysfunction, iron-deficiency anaemia, hormonal changes, psychological stress, and certain medications are all independent causes of hair shedding that must be excluded before attributing hair loss to phentermine.

It is important to consider that hair loss occurring during phentermine use may not be attributable to the medication or even to weight loss alone. A range of concurrent factors can independently or collectively contribute to increased hair shedding, and a thorough clinical assessment is necessary to identify the underlying cause.

Common causes of telogen effluvium and hair loss include:

• Thyroid dysfunction — both hypothyroidism and hyperthyroidism are well-recognised causes of diffuse hair loss and should be excluded with a blood test (thyroid function tests)

• Anaemia — iron-deficiency anaemia is particularly prevalent in women and can cause significant shedding

• Hormonal changes — including polycystic ovary syndrome (PCOS), postpartum hormonal shifts, or the perimenopause

• Psychological stress and anxiety — emotional stress is a recognised trigger for telogen effluvium

• Crash dieting or very low-calorie diets — even without medication, severe caloric restriction alone can precipitate hair loss

• Underlying autoimmune conditions — such as alopecia areata, which typically causes patchy rather than diffuse hair loss

• Certain medications — including anticoagulants (e.g. warfarin, heparin), oral retinoids, and some antidepressants; the BNF provides further detail on drug-induced alopecia

It is also worth noting that phentermine has stimulant properties and is associated with elevated heart rate and blood pressure as recognised adverse effects (as described in non-UK prescribing information and the BNF). Whilst there is no established link between phentermine's sympathomimetic action and hair follicle disruption, the overall physiological burden of stimulant use combined with caloric restriction may be relevant in susceptible individuals.

If you notice scalp redness, pain, scaling, or any signs of scarring alongside hair loss, seek prompt medical review, as these features may indicate a scarring alopecia requiring earlier specialist assessment. Identifying and addressing any coexisting causes is essential before attributing hair loss solely to phentermine.

When to Speak to a GP or Pharmacist

Seek GP advice if hair loss is sudden, patchy, accompanied by scalp inflammation, or persists beyond six months; initial investigations should include a full blood count, serum ferritin, and thyroid function tests.

Mild, diffuse hair shedding during a period of weight loss is generally self-limiting and does not usually require urgent medical attention. However, there are circumstances in which it is important to seek professional advice. A GP or pharmacist can help determine whether the hair loss is related to phentermine use, an underlying medical condition, or nutritional deficiency — and can arrange appropriate investigations.

You should contact your GP if:

• Hair loss is sudden, severe, or rapidly progressive

• You notice patchy bald areas rather than diffuse thinning, which may suggest alopecia areata

• Your scalp is painful, inflamed, red, or scaly, or you notice scarring — these features warrant prompt review to exclude scarring alopecia

• Hair loss is accompanied by other symptoms such as fatigue, unexplained weight changes, cold intolerance, or skin changes — which may indicate thyroid disease

• You are experiencing significant psychological distress as a result of hair changes

• Hair loss persists for more than six months after stabilising your weight or diet

• You are concerned about nutritional deficiencies and would like blood tests

In line with NICE CKS guidance on alopecia, initial investigations typically include a full blood count (FBC), serum ferritin, and thyroid function tests (TFTs). Further tests — such as vitamin D, zinc, or hormonal profiles — should be guided by your clinical history and examination findings, rather than requested routinely.

A pharmacist can offer initial guidance on over-the-counter nutritional supplements and can advise on whether a GP referral is warranted. If phentermine has been prescribed, inform your prescribing clinician of any new symptoms, including hair loss, so that a full review of the treatment plan can be undertaken. Do not stop taking prescribed medication without first seeking medical advice.

Managing Hair Loss Whilst Taking Phentermine

Telogen effluvium from weight loss generally resolves within six to nine months once the trigger is addressed; nutritional support, adequate protein and iron intake, and gentle hair care are the mainstays of management.

For most individuals, hair loss associated with phentermine use or rapid weight loss is temporary and will resolve as the body adjusts. The British Association of Dermatologists (BAD) notes that telogen effluvium generally has a good prognosis, with hair regrowth typically occurring within six to nine months once the underlying trigger is addressed. There are several practical steps that can help minimise shedding and support healthy hair regrowth during this period.

Nutritional support is the cornerstone of management. Ensuring adequate intake of protein, iron, and zinc is particularly important. A balanced diet that meets daily nutritional requirements should be maintained even whilst following a calorie-controlled plan. If dietary intake is insufficient, a healthcare professional may recommend targeted supplementation following blood test results. Self-prescribing high-dose supplements without prior testing is not advised, as excess intake of certain nutrients (such as vitamin A) can itself contribute to hair loss, and routine biotin supplementation is not recommended in the absence of confirmed deficiency.

Practical hair care measures can help reduce mechanical stress on fragile hair:

• Use a gentle, sulphate-free shampoo and avoid excessive heat styling

• Allow hair to air dry where possible and minimise tight hairstyles

• Avoid chemical treatments such as bleaching or perming during periods of active shedding

• Use a wide-toothed comb rather than a brush to detangle wet hair

In cases where hair loss is persistent or distressing, a GP may refer to a dermatologist for further assessment. Topical minoxidil is available over the counter in the UK and is a licensed treatment for androgenetic alopecia (pattern hair loss). It is not specifically licensed or indicated for telogen effluvium, and evidence for its use in this context is limited. Addressing the root cause — whether nutritional, hormonal, or stress-related — remains the most effective long-term strategy, as supported by NICE CKS and Primary Care Dermatology Society (PCDS) guidance on telogen effluvium.

UK Prescribing Guidelines and Availability of Phentermine

Phentermine has no UK marketing authorisation and is a Schedule 3 controlled drug; NICE recommends orlistat, liraglutide, or semaglutide as licensed pharmacotherapy options for obesity management.

Phentermine occupies a complex regulatory position in the United Kingdom. It does not currently hold a UK marketing authorisation, meaning there is no MHRA-approved product licence or SmPC for phentermine on the UK market. Clinicians wishing to prescribe it would need to do so under a special clinical exemption, and patients should be aware that it is not a routinely available or recommended treatment within NHS clinical pathways.

In terms of legal classification, phentermine is listed as a Schedule 3 controlled drug under the Misuse of Drugs Regulations 2001 (as confirmed by the UK Government/Home Office controlled drugs list). This means it is subject to specific prescribing, dispensing, and record-keeping requirements under UK law.

Current NICE guidance on obesity management recommends lifestyle interventions and behavioural support as the foundation of treatment. Where pharmacotherapy is indicated, orlistat remains the established first-line licensed option in primary care. More recently, NICE has approved GLP-1 receptor agonists for weight management in specific patient groups: liraglutide (Saxenda) via NICE TA664 and semaglutide (Wegovy) via NICE TA875. Phentermine is not included within any current NICE-recommended treatment algorithm for obesity. For up-to-date primary care guidance, refer to NICE CKS: Obesity.

Phentermine may occasionally be considered by specialist obesity clinics or private practitioners in the UK on a named-patient or unlicensed basis, but this requires careful clinical justification given its stimulant properties, potential for dependence, and cardiovascular contraindications. Any duration of use referenced in non-UK sources (such as the commonly cited 12-week course from US labelling) reflects prescribing information from other jurisdictions and is not directly applicable in the UK context.

Patients who have obtained phentermine through online or overseas sources without a valid UK prescription should be aware of the significant safety and legal risks involved, including restrictions on importing controlled drugs into the UK. Anyone considering phentermine for weight management is strongly encouraged to consult their GP or a registered specialist, who can assess suitability, discuss evidence-based licensed alternatives, and ensure appropriate monitoring — including for side effects such as hair changes — throughout any course of treatment.

Frequently Asked Questions